Fuzuloparib and apatinib before surgery for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer that is high-grade or moderately/poorly differentiated.
- You are between 18 and 70 years old and in generally good health (able to do daily activities).
- A tumor sample or blood test shows you have a genetic change called HRD (homologous recombination deficiency).
- Surgery to remove the tumor is not possible at this time (either because the tumor is too widespread or your health doesn't allow it).
- You have not had prior treatment for ovarian cancer (including chemotherapy, PARP inhibitors, or certain anti-angiogenic drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two investigational drug combinations (fluzoparib plus famitinib, or fluzoparib plus SHR-1701) given before surgery to shrink ovarian cancer. The goal is to see which approach helps more with tumor reduction and making surgery more effective.
This trial tests two oral medications, pamiparib and surufatinib, given before surgery to shrink advanced ovarian cancer. The goal is to make surgery more successful and potentially improve outcomes for patients who cannot have surgery right away.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.